Clinical Trials Browser

Phase 2 × OTHER × Multiple Advanced Tumors After PD-1 Therapy Failure × Clear all

NCT07095803 2025-07-31

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Phase 2 Not yet recruiting

Multiple Advanced Tumors After PD-1 Therapy Failure